Principal Financial Group
TOVX icon

Principal Financial Group’s Theriva Biologics TOVX Stock Holding History

Principal Financial Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed -$11K – 2288
2017
Q1 		$11K Hold
2
– – ﹤0.01% 2205
2016
Q4 		$14K Hold
2
– – ﹤0.01% 2226
2016
Q3 		$23K Hold
2
– – ﹤0.01% 2160
2016
Q2 		$24K Buy
+2
New +$37.6K ﹤0.01% 2158

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Principal Financial Group's TOVX Position: Q2 2017 in Review

Principal Financial Group sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 2 shares — an estimated $11K sold.

Principal Financial Group first reported a position in TOVX in Q2 2016 and held it in 4 quarters. The position peaked at $24K in Q2 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • Principal Financial Group reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • Principal Financial Group sold 2 Theriva Biologics shares in Q2 2017, an estimated $11K.
  • Principal Financial Group first reported a position in Theriva Biologics in Q2 2016 and held it in 4 quarters.
  • Principal Financial Group's Theriva Biologics position peaked at $24K in Q2 2016.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Principal Financial Group's 13F filing for Q2 2017, filed 8 Aug 2017.